CO6160237A2 - Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden - Google Patents
Pirazinonas y pirazinoles sustituidos y composiciones que los comprendenInfo
- Publication number
- CO6160237A2 CO6160237A2 CO09016704A CO09016704A CO6160237A2 CO 6160237 A2 CO6160237 A2 CO 6160237A2 CO 09016704 A CO09016704 A CO 09016704A CO 09016704 A CO09016704 A CO 09016704A CO 6160237 A2 CO6160237 A2 CO 6160237A2
- Authority
- CO
- Colombia
- Prior art keywords
- optionally substituted
- pyrazin
- imidazo
- fused
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
1.- Al menos una entidad química seleccionada de compuestos de la fórmula I y compuestos de la fórmula II:y sales farmacéuticamente aceptables del mismo, en donde R1 y R4 están seleccionados, de modo independiente, de hidrógeno, halo, hidroxi, acilo opcionalmente sustituido, alquilo opcionalmente sustituido, amino opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, alcoxi opcionalmente sustituido, aminocarbonilo opcionalmente sustituido, sulfonilo, sulfanilo, sulfinilo, carboxi, alcoxicarbonilo opcionalmente sustituido y ciano; y, de modo alternativo, R4 y R1, tomados junto con cualquier átomo interviniente, forman un sistema de anillos fusionados seleccionados de arilo fusionado opcionalmente sustituido, heteroarilo fusionado opcionalmente sustituido, cicloalquilo fusionado opcionalmente sustituido y heterocicloalquilo fusionado opcionalmente sustituido; y R2 está seleccionado de alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido y heterocicloalquilo opcionalmente sustituido; siempre que R1 no sea hex-1-enilo; y también siempre que el compuesto de la fórmula I o el compuesto de la fórmula II no sea (S)-6-bromo-1-(1-feniletil)-1H-imidazo [4,5-b]pirazin-2 (3H) -ona; 1, 5, 6-trimetil-1H-imidazo [4, 5-b] pirazin-2 (3H) -ona; 1-metil-1H-imidazo [4,5-b] pirazin-2 (3H) -ona; 6-bromo-1- (3-nitrobencil)-1H-imidazo [4,5-b] pirazin-2 (3H)- ona; 5-(hidroximetil)-1,6-dimetil-1H-imidazo [4,5-b] pirazin-2(3H)- ona; o 1- (piperidin-4-il) -1H-imidazo [4,5-b] pirazin-2 (3H)-ona. 2.- Al menos una entidad química de acuerdo con la reivindicación 1, en donde R2 está seleccionado de alquilo inferior opcionalmente sustituido, cicloalquilo opcionalmente sustituido, alcoxi opcionalmente sustituido y heterocicloalquilo opcionalmente sustituido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83527206P | 2006-08-02 | 2006-08-02 | |
US92105407P | 2007-03-30 | 2007-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6160237A2 true CO6160237A2 (es) | 2010-05-20 |
Family
ID=38997712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09016704A CO6160237A2 (es) | 2006-08-02 | 2009-02-19 | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden |
Country Status (27)
Country | Link |
---|---|
US (3) | US7598248B2 (es) |
EP (4) | EP2666777A1 (es) |
JP (4) | JP5249217B2 (es) |
KR (1) | KR101410453B1 (es) |
CN (1) | CN102993204A (es) |
AR (1) | AR062196A1 (es) |
AU (1) | AU2007281468B2 (es) |
BR (1) | BRPI0714725B1 (es) |
CA (1) | CA2659336C (es) |
CL (1) | CL2007002252A1 (es) |
CO (1) | CO6160237A2 (es) |
DK (2) | DK2069352T5 (es) |
EA (1) | EA017925B1 (es) |
ES (2) | ES2439590T3 (es) |
HK (3) | HK1131785A1 (es) |
HR (1) | HRP20160036T1 (es) |
HU (1) | HUE026571T2 (es) |
IL (1) | IL196767A (es) |
MX (1) | MX2009001170A (es) |
NZ (1) | NZ574888A (es) |
PE (1) | PE20080524A1 (es) |
PL (2) | PL2583970T3 (es) |
PT (2) | PT2583970E (es) |
RS (1) | RS54542B1 (es) |
TW (1) | TWI386412B (es) |
WO (1) | WO2008016669A2 (es) |
ZA (1) | ZA200900976B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
PL2583970T3 (pl) * | 2006-08-02 | 2016-05-31 | Cytokinetics Inc | Określone cząstki chemiczne, kompozycje i sposoby zawierające imidazopirymidyny |
US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
MX337906B (es) * | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
US7851484B2 (en) * | 2007-03-30 | 2010-12-14 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
JP2011510985A (ja) * | 2008-02-04 | 2011-04-07 | サイトキネティックス, インコーポレイテッド | 特定の化学的実体、組成物および方法 |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
EP3037421A3 (en) | 2008-11-25 | 2016-11-30 | University Of Rochester | Mlk inhibitors and methods of use |
SG10201500511TA (en) | 2009-10-26 | 2015-03-30 | Signal Pharm Llc | Methods Of Synthesis And Purification Of Heteroaryl Compounds |
WO2011149950A2 (en) | 2010-05-24 | 2011-12-01 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
SG10201605707UA (en) * | 2011-07-13 | 2016-09-29 | Cytokinetics Inc | Combination als therapy |
KR101978537B1 (ko) * | 2011-10-19 | 2019-05-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
JP6076370B2 (ja) | 2011-12-02 | 2017-02-08 | シグナル ファーマシューティカルズ,エルエルシー | 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((トランス)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オンの薬剤組成物、その固体形態、およびその使用方法 |
ES2742398T3 (es) | 2012-02-24 | 2020-02-14 | Signal Pharm Llc | Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa |
US20150065525A1 (en) * | 2012-04-02 | 2015-03-05 | Cytokinetics, Inc. | Methods for improving diaphragm function |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
WO2014085795A1 (en) | 2012-11-30 | 2014-06-05 | University Of Rochester | Mixed lineage kinase inhibitors for hiv/aids therapies |
SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
JP6382948B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及びシチジン類似体を含む組合せ療法 |
TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
CA2908830C (en) | 2013-04-17 | 2021-12-07 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
PE20160041A1 (es) | 2013-04-17 | 2016-01-28 | Signal Pharm Llc | FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA |
US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
EP2986322A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
TWI631950B (zh) | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 藉二氫吡𠯤并吡𠯤治療癌症 |
EP3003313A1 (en) | 2013-05-29 | 2016-04-13 | Signal Pharmaceuticals, LLC | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ,エルエルシー | 1−エチル−7−(2−メチル−6−(1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
PL3137622T3 (pl) | 2014-04-29 | 2022-05-09 | Cytokinetics, Inc. | Sposoby redukowania spadku pojemności życiowej |
KR20170024120A (ko) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물 |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
PL3413892T3 (pl) | 2016-02-12 | 2022-06-13 | Cytokinetics, Incorporated | Pochodne tetrahydroizochinoliny |
CN110996955A (zh) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 |
AU2021373814A1 (en) * | 2020-11-06 | 2023-05-25 | Cytokinetics, Inc. | Bicyclic 1,4-diazepanones and therapeutic uses thereof |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
US3507866A (en) * | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
IT1156732B (it) * | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
JPH03502326A (ja) | 1988-01-28 | 1991-05-30 | ポリゲン ホールディング コーポレイション | 成長ホルモン放出活性を有するポリペプチド化合物類 |
AU637316B2 (en) | 1988-01-28 | 1993-05-27 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
US4943573A (en) * | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
JPH0641135A (ja) * | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | イミダゾプテリジン誘導体及びその製造方法 |
JPH0641134A (ja) | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | ピリミドプテリジン誘導体及びその製造方法 |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
DE69636677D1 (de) | 1995-12-13 | 2006-12-14 | Univ California | Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP2002517396A (ja) | 1998-06-04 | 2002-06-18 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症性化合物 |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6410254B1 (en) | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
BR0014818A (pt) | 1999-10-08 | 2002-06-18 | Gruenenthal Gmbh | Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica |
MXPA02002837A (es) | 1999-10-08 | 2002-08-30 | Gr Nenthal Gmbh | Derivados biciclicos de imidazo-5-il-amina. |
US7148380B2 (en) | 2000-02-07 | 2006-12-12 | Yisheng Zhang | Bio-energy muscle relaxants |
DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
GB0212048D0 (en) * | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
US7399866B2 (en) * | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
GB2400101A (en) * | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
CA2529196A1 (en) * | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
AU2004253543B2 (en) | 2003-07-01 | 2009-02-19 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2007515429A (ja) | 2003-12-19 | 2007-06-14 | エリクシアー ファーマシューティカルズ, インコーポレイテッド | 障害を治療する方法 |
JP2007529422A (ja) | 2004-01-29 | 2007-10-25 | エリクシアー ファーマシューティカルズ, インコーポレイテッド | 抗ウイルス治療 |
US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
JP2008514628A (ja) * | 2004-09-24 | 2008-05-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 蛋白質キナーゼ類のイミダゾ{4,5−b}ピラジノン阻害剤 |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
CN101189238A (zh) * | 2005-02-16 | 2008-05-28 | 先灵公司 | 具有cxcr3拮抗剂活性的哌嗪-哌啶 |
US7820664B2 (en) | 2007-01-19 | 2010-10-26 | Bayer Schering Pharma Ag | Inhibitors of MEK |
EP1959962A2 (en) * | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US8796293B2 (en) * | 2006-04-25 | 2014-08-05 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
US20090082370A1 (en) * | 2006-04-25 | 2009-03-26 | Neil Thomas Thompson | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents |
TWI339283B (en) * | 2006-07-14 | 2011-03-21 | Chimei Innolux Corp | Frame assembly of flat display panel |
US20100173930A1 (en) | 2006-08-01 | 2010-07-08 | Alex Muci | Certain Chemical Entities, Compositions and Methods |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
PL2583970T3 (pl) * | 2006-08-02 | 2016-05-31 | Cytokinetics Inc | Określone cząstki chemiczne, kompozycje i sposoby zawierające imidazopirymidyny |
CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
MX337906B (es) * | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
US7851484B2 (en) | 2007-03-30 | 2010-12-14 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
JP5313883B2 (ja) * | 2007-04-18 | 2013-10-09 | キッセイ薬品工業株式会社 | 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途 |
US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
EP3037421A3 (en) | 2008-11-25 | 2016-11-30 | University Of Rochester | Mlk inhibitors and methods of use |
-
2007
- 2007-08-01 PL PL13151376T patent/PL2583970T3/pl unknown
- 2007-08-01 EP EP13176575.2A patent/EP2666777A1/en not_active Withdrawn
- 2007-08-01 EP EP07810993.1A patent/EP2069352B9/en active Active
- 2007-08-01 KR KR1020097004317A patent/KR101410453B1/ko active IP Right Grant
- 2007-08-01 PT PT131513764T patent/PT2583970E/pt unknown
- 2007-08-01 WO PCT/US2007/017235 patent/WO2008016669A2/en active Application Filing
- 2007-08-01 DK DK07810993.1T patent/DK2069352T5/en active
- 2007-08-01 CN CN2012103130559A patent/CN102993204A/zh active Pending
- 2007-08-01 CA CA2659336A patent/CA2659336C/en active Active
- 2007-08-01 PT PT78109931T patent/PT2069352E/pt unknown
- 2007-08-01 RS RS20150875A patent/RS54542B1/en unknown
- 2007-08-01 ES ES07810993.1T patent/ES2439590T3/es active Active
- 2007-08-01 JP JP2009522867A patent/JP5249217B2/ja active Active
- 2007-08-01 NZ NZ574888A patent/NZ574888A/en unknown
- 2007-08-01 DK DK13151376.4T patent/DK2583970T3/en active
- 2007-08-01 US US11/888,902 patent/US7598248B2/en active Active
- 2007-08-01 EP EP13151376.4A patent/EP2583970B1/en active Active
- 2007-08-01 BR BRPI0714725-2A patent/BRPI0714725B1/pt active IP Right Grant
- 2007-08-01 EA EA200900242A patent/EA017925B1/ru unknown
- 2007-08-01 AU AU2007281468A patent/AU2007281468B2/en not_active Ceased
- 2007-08-01 ES ES13151376.4T patent/ES2558517T3/es active Active
- 2007-08-01 HU HUE13151376A patent/HUE026571T2/hu unknown
- 2007-08-01 PL PL07810993T patent/PL2069352T3/pl unknown
- 2007-08-01 MX MX2009001170A patent/MX2009001170A/es active IP Right Grant
- 2007-08-01 EP EP15187559.8A patent/EP2995619B1/en active Active
- 2007-08-02 TW TW096128335A patent/TWI386412B/zh active
- 2007-08-02 PE PE2007001005A patent/PE20080524A1/es active IP Right Grant
- 2007-08-02 AR ARP070103421A patent/AR062196A1/es active IP Right Grant
- 2007-08-02 CL CL200702252A patent/CL2007002252A1/es unknown
-
2009
- 2009-01-28 IL IL196767A patent/IL196767A/en not_active IP Right Cessation
- 2009-02-11 ZA ZA2009/00976A patent/ZA200900976B/en unknown
- 2009-02-19 CO CO09016704A patent/CO6160237A2/es unknown
- 2009-10-05 US US12/573,730 patent/US7956056B2/en active Active
- 2009-12-15 HK HK09111751.7A patent/HK1131785A1/xx not_active IP Right Cessation
-
2010
- 2010-04-22 US US12/765,820 patent/US8293761B2/en active Active
-
2013
- 2013-04-11 JP JP2013082653A patent/JP5746254B2/ja active Active
- 2013-10-11 HK HK13111483.6A patent/HK1184446A1/zh not_active IP Right Cessation
-
2015
- 2015-05-07 JP JP2015094580A patent/JP6254546B2/ja active Active
-
2016
- 2016-01-13 HR HRP20160036T patent/HRP20160036T1/hr unknown
- 2016-09-15 HK HK16110919.9A patent/HK1222843A1/zh unknown
-
2017
- 2017-11-30 JP JP2017230072A patent/JP6538809B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
AR054365A1 (es) | Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. | |
ES2567311T3 (es) | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP | |
AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
AR065280A1 (es) | Agentes antiparasitarios | |
PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
BRPI0413233A (pt) | novos compostos | |
PE20130155A1 (es) | Derivados de ariletinilo | |
AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
AR056888A1 (es) | Derivados de heterociclil imidazol | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
GT200600134A (es) | Compuestos novedosos de derivados de aminosulfonilo | |
ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
AR047678A1 (es) | Derivados de benzamidas y su uso como activadores de glucoquinasa | |
DOP2010000046A (es) | Compuestos de biciclolactama sustituida | |
AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
AR061181A1 (es) | Compuestos de aziridinil-epotilona | |
AR063529A1 (es) | Compuestos de pirazolina | |
AR070463A1 (es) | Compuestos de amina y eter que modulan el receptor cb2 | |
CO6321266A2 (es) | Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso | |
WO2009010789A3 (en) | Pyrimidine derivatives 934 | |
CO6220935A2 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 |